Elevated_JJ
glucocorticoid_NN
receptor_NN
concentrations_NNS
before_IN
and_CC
after_IN
glucocorticoid_NN
therapy_NN
in_IN
peripheral_JJ
mononuclear_JJ
leukocytes_NNS
of_IN
patients_NNS
with_IN
atopic_JJ
dermatitis_NN
._.

The_DT
number_NN
and_CC
affinity_NN
of_IN
glucocorticoid_NN
binding_NN
sites_NNS
in_IN
peripheral_JJ
mononuclear_JJ
leukocytes_NNS
of_IN
patients_NNS
with_IN
atopic_JJ
dermatitis_NN
-LRB-_-LRB-
AD_NN
-RRB-_-RRB-
and_CC
healthy_JJ
controls_NNS
were_VBD
determined_VBN
under_IN
baseline_NN
conditions_NNS
and_CC
after_IN
a_DT
defined_VBN
oral_JJ
glucocorticoid_NN
treatment_NN
._.

Patients_NNS
with_IN
AD_NN
-LRB-_-LRB-
n_NN
=_JJ
15_CD
-RRB-_-RRB-
exhibited_VBD
significantly_RB
more_RBR
glucocorticoid_NN
receptors_NNS
-LRB-_-LRB-
GR_NN
-RRB-_-RRB-
per_IN
cell_NN
than_IN
the_DT
control_JJ
group_NN
-LRB-_-LRB-
n_NN
=_JJ
22_CD
-RRB-_-RRB-
,_,
while_IN
the_DT
GR_NN
affinity_NN
did_VBD
not_RB
differ_VB
._.

Methylprednisolone_NN
treatment_NN
resulted_VBD
in_IN
a_DT
significant_JJ
reduction_NN
of_IN
the_DT
GR_NN
sites_NNS
per_IN
cell_NN
in_IN
the_DT
steroid-treated_JJ
control_NN
group_NN
-LRB-_-LRB-
n_NN
=_JJ
10_CD
-RRB-_-RRB-
in_IN
contrast_NN
to_TO
the_DT
patients_NNS
._.

The_DT
dissociation_NN
constant_NN
was_VBD
not_RB
affected_VBN
by_IN
methylprednisolone_NN
treatment_NN
in_IN
either_DT
group_NN
._.

In_IN
view_NN
of_IN
the_DT
therapeutic_JJ
efficiency_NN
of_IN
glucocorticoids_NNS
in_IN
AD_NN
and_CC
findings_NNS
of_IN
abnormal_JJ
cAMP_NN
and_CC
cAMP-phosphodiesterase_NN
activity_NN
,_,
the_DT
elevated_JJ
GR_NN
concentrations_NNS
in_IN
AD_NN
lend_VBP
support_NN
to_TO
the_DT
hypothesis_NN
of_IN
a_DT
compensatory_JJ
GR_NN
upregulation_NN
due_JJ
to_TO
an_DT
insufficient_JJ
action_NN
of_IN
endogenous_JJ
cortisol_NN
or_CC
to_TO
altered_JJ
cAMP-induced_JJ
GR_NN
expression_NN
._.

